Xbox Game Streaming Still Down After 24 Hours, Reminding Us That Your Phone Isn't Actually An XboxCPI(M) to strengthen its social media presence in BengalTiE Global Summit 2024 in Bangalore
CORAL GABLES, Fla. (AP) — Miami probably was one win away from getting into the College Football Playoff. Iowa State definitely was one win away. Their consolation prize of sorts: playing one another. The Hurricanes and Cyclones — a meteorological matchup — have accepted bids to the Pop-Tarts Bowl, to be played Dec. 28 in Orlando, Florida. Iowa State (10-3) is looking for its first 11-win season in the program's 133-year history, and Miami (10-2) is seeking its first 11-win season since 2003. Miami's loss at Syracuse to close the regular season wound up being the game the Hurricanes could point to as the reason they missed out on the CFP. Iowa State could have played its way in and lost the Big 12 title game to CFP-bound Arizona State on Saturday. “I think everyone that doesn't get in feels disappointment,” Miami coach Mario Cristobal said. “We feel the onus of just doing better. Just do better, go forward, have an opportunity to get better.” It's essentially the same task for both teams: regrouping after seeing the playoff slip away. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Kyle Whittingham will return next season as Utah's coach. There has been some speculation about Whittingham's future plans, but the 65-year-old coaching veteran announced Sunday that he has no plans to step aside. And he channeled Michael Jordan in signaling his intention to return for the 2025 season. For immediate release📰 We are looking forward to 2025!!️ #GoUtes | @UtahCoachWhitt pic.twitter.com/jq9BnjypgO Whittingham has led the program since 2005 but saw a streak of 10 consecutive winning seasons snapped this year as the Utes -- picked to win the Big 12 in their first season as members -- were plagued by injuries yet again. Utah started the season 4-0 before enduring a seven-game losing streak that included a heartbreaking home loss to rival BYU , which was undefeated and ranked No. 9 in the country at the time. Utah closed out the regular season with a win over UCF , but finished 5-7 to miss out on a bowl game. With Utes defensive coordinator Morgan Scalley already carrying the "coach-in-waiting" label in Salt Lake City, some wondered whether Whittingham would step aside. Instead, he will be back on the sidelines for his 21st season as coach and 32nd overall with the program. Utah has struggled offensively in the past two seasons with quarterback Cam Rising dealing with multiple serious injuries. Andy Ludwig, Utah's offensive coordinator since 2019, stepped down from his position on Oct. 20. Following the conclusion of the regular season, Whittingham hired Jason Beck from New Mexico to serve as offensive coordinator next season. In all, Whittingham has a 167-86 record with three conference titles -- one in the Mountain West and two in the Pac-12 -- during his time leading the program.
None
Steelers QB Russell Wilson is spreading the wealth on offenseBeneficient Enters into Agreement to Acquire Mercantile Bank International to Expand its Alternative Asset Custody ServicesMeet the 12 CFP Title Contenders: No. 12 Clemson
An online debate over foreign workers in tech shows tensions in Trump's political coalition
NoneTens of thousands of Spaniards protest housing crunch and high rents in Barcelona
Reports: Kings fire coach Mike Brown2 Growth Stocks Set to Skyrocket in 2025 and Beyond - The Motley Fool CanadaREDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The shares of common stock issued and sold in the offering include 2,445,652 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were $862.5 million. All shares and pre-funded warrants in the offering were offered by Revolution Medicines. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities acted as joint book-running managers for the offering. UBS Investment Bank acted as lead manager. A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on March 4, 2024, and automatically became effective upon filing. This offering was made solely by means of a prospectus. A copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, a copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552. Revolution Medicines Investors & Media Contacts: investors@revmed.com; media@revmed.com